PGL5001 Proof of Concept Study in Inflammatory Endometriosis
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating
the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001
orally administered for up to 5 months with concomitant DMPA administration for the treatment
of laparoscopically diagnosed inflammatory endometriosis. The part A1 is open-label, the
parts A2 and B are double-blind.
The target population will be women of reproductive age and suffering from newly diagnosed
peritoneal and/or ovarian endometriosis.